<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011049</url>
  </required_header>
  <id_info>
    <org_study_id>FID33</org_study_id>
    <secondary_id>UTN: U1111-1111-5095</secondary_id>
    <nct_id>NCT01011049</nct_id>
  </id_info>
  <brief_title>Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM</brief_title>
  <official_title>Safety and Immunogenicity of Revaccination With Influenza Vaccine in Healthy Adult Subjects Aged 18 to 64 Years Who Were Previously Vaccinated With Fluzone ID or Fluzone IM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to generate additional data on the immunogenicity and safety of
      revaccination with Fluzone Intradermal (ID) or Fluzone Intramuscular (IM) vaccine.

      Primary Objective:

        -  To evaluate and describe the safety profile of revaccination with Fluzone ID for all
           participants.

      Secondary Objective:

        -  To describe immunogenicity following revaccination with Fluzone ID or Fluzone IM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants, who previously received either Fluzone ID or Fluzone IM in Study FID31 (NCT
      00772109), will receive one dose of either the same or the alternative vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site and Systemic Reactions After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine</measure>
    <time_frame>Day 0 through Day 7 post-vaccination</time_frame>
    <description>Solicited injection site reactions: Erythema (redness), Swelling, Induration, Pain, Pruritus, Ecchymosis. Solicited systemic reactions: Headache, Myalgia, Malaise, Shivering, Fever (temperature).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) Before and After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine</measure>
    <time_frame>Day 0 and Day 28 post-vaccination</time_frame>
    <description>Serum antibody titers for influenza vaccine serogroups A/H1N1, A/H3N2, and B were assessed by the hemagglutinin inhibition (HAI) assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Seroprotection Before and After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine.</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Seroprotection was defined as a hemagglutinin inhibition (HAI) titer ≥ 1:40 at Day 28 post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Achieved Seroconversion After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine</measure>
    <time_frame>Day 28 post vaccination</time_frame>
    <description>Seroconversion was defined as either a pre vaccination hemagglutinin inhibition (HAI) titer &lt; 1:10 and a post vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum 4 fold increase at 28 days post-vaccination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1250</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1: Fluzone ID After Fluzone ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Fluzone intradermal (ID) following Fluzone ID in Study FID31</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Fluzone IM After Fluzone ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Fluzone intramuscular (IM) following Fluzone ID in Study FID31</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Fluzone IM After Fluzone IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Fluzone intramuscular (IM) following Fluzone IM in Study FID31</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Fluzone ID After Fluzone IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Fluzone intradermal (ID) following Fluzone intramuscular (IM) in Study FID31</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine USP Trivalent Types A and B</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Group 1: Fluzone ID After Fluzone ID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine USP Trivalent Types A and B</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 2: Fluzone IM After Fluzone ID</arm_group_label>
    <other_name>Fluzone® 2009/2010 Northern Hemisphere Formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine USP Trivalent Types A and B</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 3: Fluzone IM After Fluzone IM</arm_group_label>
    <other_name>Fluzone® 2009/2010 Northern Hemisphere Formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine USP Trivalent Types A and B</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Group 4: Fluzone ID After Fluzone IM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Aged 18 to 64 years on the day of vaccination in study FID33

          -  Enrolled in and completed study FID31 (NCT 00772109) and received the correct vaccine
             (Fluzone ID or Fluzone® IM) for the group to which they were randomized

          -  Informed consent form signed and dated

          -  Able to attend all scheduled visits and to comply with all trial procedures

          -  For a woman of child-bearing potential, avoid becoming pregnant (use of an effective
             method of contraception or abstinence) for at least 4 weeks prior to vaccination,
             until at least 4 weeks after vaccination

        Exclusion Criteria :

          -  Known systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or to a vaccine containing any of the
             same substances

          -  For a woman of child-bearing potential: known pregnancy or positive serum/urine
             pregnancy test

          -  Breast-feeding woman

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the four weeks preceding the trial vaccination

          -  Planned participation in another clinical trial during the present trial period
             (observational trials will be allowed)

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic corticosteroids therapy

          -  Chronic illness, at a stage that could interfere with trial conduct or completion, in
             the opinion of the investigator

          -  Current alcohol abuse or drug addiction that may interfere with the subject's ability
             to comply with trial procedures

          -  Receipt of blood or blood-derived products in the past 3 months, that might interfere
             with the assessment of immune response

          -  Receipt of any vaccination in the 4 weeks preceding the trial vaccination

          -  Planned receipt of any vaccine in the 4 weeks following the trial vaccination

          -  Known human immunodeficiency virus (HIV), hepatitis B surface (HBs) antigen, or
             Hepatitis C seropositivity.

          -  Previous vaccination against influenza in the past 6 months with the trial vaccine or
             another vaccine

          -  Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding
             inclusion contraindicating IM vaccination

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent

          -  Neoplastic disease or any hematologic malignancy, (those who have localized skin or
             prostate cancer that is stable at the time of vaccination in the absence of therapy,
             as well as subjects who have a history of neoplastic disease and who have been disease
             free for ≥ 5 years will not be excluded).

          -  Personal or family history of Guillain-Barré Syndrome

        Temporary Exclusion Criteria:

        A prospective subject should not be included in the study until the following conditions
        and/or symptoms are resolved:

          -  Febrile illness (temperature ≥ 37.5°C [or ≥ 99.5°F]) or moderate or severe acute
             illness/infection on the day of vaccination, according to investigator judgment

          -  Signs and symptoms of an acute infectious respiratory illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <zip>19020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <results_first_submitted>July 14, 2011</results_first_submitted>
  <results_first_submitted_qc>July 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2011</results_first_posted>
  <disposition_first_submitted>March 31, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>March 31, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 2, 2010</disposition_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Fluzone Vaccine</keyword>
  <keyword>Intradermal Injections</keyword>
  <keyword>Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled and from 23 September 2009 to 16 October 2009 in 46 medical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 1248 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Fluzone ID After Fluzone ID</title>
          <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone ID vaccine in Study FID31 (NCT00772109)</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Fluzone IM After Fluzone ID</title>
          <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone intradermal (ID) vaccine in Study FID31 (NCT00772109)</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Fluzone IM After Fluzone IM</title>
          <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone IM vaccine in Study FID31 (NCT00772109)</description>
        </group>
        <group group_id="P4">
          <title>Group 4: Fluzone ID After Fluzone IM</title>
          <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone intramuscular (IM) vaccine in Study FID31 (NCT00772109)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="507"/>
                <participants group_id="P2" count="252"/>
                <participants group_id="P3" count="243"/>
                <participants group_id="P4" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="506"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="239"/>
                <participants group_id="P4" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Fluzone ID After Fluzone ID</title>
          <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone ID vaccine in Study FID31 (NCT00772109)</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Fluzone IM After Fluzone ID</title>
          <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone intradermal (ID) vaccine in Study FID31 (NCT00772109)</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Fluzone IM After Fluzone IM</title>
          <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone IM vaccine in Study FID31 (NCT00772109)</description>
        </group>
        <group group_id="B4">
          <title>Group 4: Fluzone ID After Fluzone IM</title>
          <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone intramuscular (IM) vaccine in Study FID31 (NCT00772109)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="507"/>
            <count group_id="B2" value="252"/>
            <count group_id="B3" value="243"/>
            <count group_id="B4" value="246"/>
            <count group_id="B5" value="1248"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="507"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="242"/>
                    <measurement group_id="B4" value="246"/>
                    <measurement group_id="B5" value="1247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.2" spread="13.10"/>
                    <measurement group_id="B2" value="44.8" spread="13.26"/>
                    <measurement group_id="B3" value="45.8" spread="12.74"/>
                    <measurement group_id="B4" value="43.7" spread="12.78"/>
                    <measurement group_id="B5" value="45" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="324"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="155"/>
                    <measurement group_id="B5" value="798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="507"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="243"/>
                    <measurement group_id="B4" value="246"/>
                    <measurement group_id="B5" value="1248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
        <description>Solicited injection site reactions: Erythema (redness), Swelling, Induration, Pain, Pruritus, Ecchymosis. Solicited systemic reactions: Headache, Myalgia, Malaise, Shivering, Fever (temperature).</description>
        <time_frame>Day 0 through Day 7 post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated subjects with available reaction data, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Fluzone ID After Fluzone ID</title>
            <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone ID vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Fluzone IM After Fluzone ID</title>
            <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone intradermal (ID) vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Fluzone IM After Fluzone IM</title>
            <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone IM vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Fluzone ID After Fluzone IM</title>
            <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone intramuscular (IM) vaccine in Study FID31 (NCT00772109)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
          <description>Solicited injection site reactions: Erythema (redness), Swelling, Induration, Pain, Pruritus, Ecchymosis. Solicited systemic reactions: Headache, Myalgia, Malaise, Shivering, Fever (temperature).</description>
          <population>Safety analysis was on all enrolled and vaccinated subjects with available reaction data, intent-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="249"/>
                <count group_id="O3" value="243"/>
                <count group_id="O4" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="147"/>
                    <measurement group_id="O4" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pruritus (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Prevents Daily Activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Prevents Daily Activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Prevents Daily Activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering (Prevents Daily Activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (&gt; 102.2 ºF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) Before and After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
        <description>Serum antibody titers for influenza vaccine serogroups A/H1N1, A/H3N2, and B were assessed by the hemagglutinin inhibition (HAI) assay.</description>
        <time_frame>Day 0 and Day 28 post-vaccination</time_frame>
        <population>Serum antibody geometric mean titers were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Fluzone ID After Fluzone ID</title>
            <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone ID vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Fluzone IM After Fluzone ID</title>
            <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone intradermal (ID) vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Fluzone IM After Fluzone IM</title>
            <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone IM vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Fluzone ID After Fluzone IM</title>
            <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone intramuscular (IM) vaccine in Study FID31 (NCT00772109)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) Before and After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
          <description>Serum antibody titers for influenza vaccine serogroups A/H1N1, A/H3N2, and B were assessed by the hemagglutinin inhibition (HAI) assay.</description>
          <population>Serum antibody geometric mean titers were assessed in the per-protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Pre-dose (Day 0; N = 495, 242, 234, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="48.8" upper_limit="60.8"/>
                    <measurement group_id="O2" value="64.8" lower_limit="55.5" upper_limit="75.7"/>
                    <measurement group_id="O3" value="51.2" lower_limit="43.4" upper_limit="60.5"/>
                    <measurement group_id="O4" value="56.3" lower_limit="48.7" upper_limit="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Post-dose (Day 28; N = 495, 242, 234, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.8" lower_limit="129.7" upper_limit="157.3"/>
                    <measurement group_id="O2" value="151.7" lower_limit="132.1" upper_limit="174.3"/>
                    <measurement group_id="O3" value="126.2" lower_limit="109.4" upper_limit="145.7"/>
                    <measurement group_id="O4" value="137.4" lower_limit="119.8" upper_limit="157.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Pre-dose (Day 0; N = 495, 242, 234, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" lower_limit="69.3" upper_limit="89.5"/>
                    <measurement group_id="O2" value="91.3" lower_limit="75.2" upper_limit="110.8"/>
                    <measurement group_id="O3" value="69.7" lower_limit="57.9" upper_limit="84.0"/>
                    <measurement group_id="O4" value="79.7" lower_limit="66.9" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Post-dose (Day 28; N = 495, 242, 234, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286.7" lower_limit="260.3" upper_limit="315.8"/>
                    <measurement group_id="O2" value="292.0" lower_limit="250.9" upper_limit="339.8"/>
                    <measurement group_id="O3" value="268.3" lower_limit="234.2" upper_limit="307.3"/>
                    <measurement group_id="O4" value="290.8" lower_limit="252.2" upper_limit="335.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Pre-dose (Day 0; N = 495, 242, 234, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="18.5" upper_limit="21.9"/>
                    <measurement group_id="O2" value="21.0" lower_limit="18.6" upper_limit="23.6"/>
                    <measurement group_id="O3" value="21.0" lower_limit="18.4" upper_limit="24.0"/>
                    <measurement group_id="O4" value="21.8" lower_limit="19.3" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Post-dose (Day 28; N = 495, 242, 234, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="68.9" upper_limit="81.7"/>
                    <measurement group_id="O2" value="85.7" lower_limit="75.5" upper_limit="97.3"/>
                    <measurement group_id="O3" value="73.9" lower_limit="64.8" upper_limit="84.1"/>
                    <measurement group_id="O4" value="72.2" lower_limit="63.1" upper_limit="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Seroprotection Before and After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine.</title>
        <description>Seroprotection was defined as a hemagglutinin inhibition (HAI) titer ≥ 1:40 at Day 28 post-vaccination.</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Serum antibody titers were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Fluzone ID After Fluzone ID</title>
            <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone ID vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Fluzone IM After Fluzone ID</title>
            <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone intradermal (ID) vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Fluzone IM After Fluzone IM</title>
            <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone IM vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Fluzone ID After Fluzone IM</title>
            <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone intramuscular (IM) vaccine in Study FID31 (NCT00772109)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Seroprotection Before and After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine.</title>
          <description>Seroprotection was defined as a hemagglutinin inhibition (HAI) titer ≥ 1:40 at Day 28 post-vaccination.</description>
          <population>Serum antibody titers were assessed in the per-protocol population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Pre-dose (Day 0; N = 495, 242, 234, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Post-dose (Day 28; N = 495, 242, 234, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Pre-dose (Day 0; N = 495, 242, 234, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Post-dose (Day 28; N = 495, 242, 234, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Pre-dose (Day 0; N = 495, 242, 234, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Post-dose (Day 28; N = 495, 242, 234, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Achieved Seroconversion After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
        <description>Seroconversion was defined as either a pre vaccination hemagglutinin inhibition (HAI) titer &lt; 1:10 and a post vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum 4 fold increase at 28 days post-vaccination.</description>
        <time_frame>Day 28 post vaccination</time_frame>
        <population>Serum antibody titers were assessed in the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Fluzone ID After Fluzone ID</title>
            <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone ID vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Fluzone IM After Fluzone ID</title>
            <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone intradermal (ID) vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Fluzone IM After Fluzone IM</title>
            <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone IM vaccine in Study FID31 (NCT00772109)</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Fluzone ID After Fluzone IM</title>
            <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone intramuscular (IM) vaccine in Study FID31 (NCT00772109)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Achieved Seroconversion After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
          <description>Seroconversion was defined as either a pre vaccination hemagglutinin inhibition (HAI) titer &lt; 1:10 and a post vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum 4 fold increase at 28 days post-vaccination.</description>
          <population>Serum antibody titers were assessed in the per protocol population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Serogroup (N = 495, 242, 234, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Serogroup (N = 495, 242, 234, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Serogroup (N = 495, 242, 234, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination for up to 6 months, post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Fluzone ID After Fluzone ID</title>
          <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone ID vaccine in Study FID31 (NCT00772109)</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Fluzone IM After Fluzone ID</title>
          <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone intradermal (ID) vaccine in Study FID31 (NCT00772109)</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Fluzone IM After Fluzone IM</title>
          <description>Participants who received Fluzone intramuscular (IM) vaccine after receiving Fluzone IM vaccine in Study FID31 (NCT00772109)</description>
        </group>
        <group group_id="E4">
          <title>Group 4: Fluzone ID After Fluzone IM</title>
          <description>Participants who received Fluzone intradermal (ID) vaccine after receiving Fluzone intramuscular (IM) vaccine in Study FID31 (NCT00772109)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pituitary tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervix haemorrhage uterine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="412" subjects_at_risk="507"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="252"/>
                <counts group_id="E3" subjects_affected="147" subjects_at_risk="243"/>
                <counts group_id="E4" subjects_affected="183" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="274" subjects_affected="274" subjects_at_risk="505"/>
                <counts group_id="E2" events="148" subjects_affected="148" subjects_at_risk="249"/>
                <counts group_id="E3" events="147" subjects_affected="147" subjects_at_risk="240"/>
                <counts group_id="E4" events="145" subjects_affected="145" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="412" subjects_affected="412" subjects_at_risk="505"/>
                <counts group_id="E2" events="54" subjects_affected="54" subjects_at_risk="249"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="240"/>
                <counts group_id="E4" events="183" subjects_affected="183" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="343" subjects_affected="343" subjects_at_risk="505"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="249"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E4" events="137" subjects_affected="137" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="310" subjects_affected="310" subjects_at_risk="505"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="249"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="240"/>
                <counts group_id="E4" events="133" subjects_affected="133" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="98" subjects_affected="98" subjects_at_risk="505"/>
                <counts group_id="E2" events="55" subjects_affected="55" subjects_at_risk="249"/>
                <counts group_id="E3" events="50" subjects_affected="50" subjects_at_risk="240"/>
                <counts group_id="E4" events="54" subjects_affected="54" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="505"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="249"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="240"/>
                <counts group_id="E4" events="25" subjects_affected="25" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="240"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="131" subjects_affected="131" subjects_at_risk="505"/>
                <counts group_id="E2" events="77" subjects_affected="77" subjects_at_risk="249"/>
                <counts group_id="E3" events="75" subjects_affected="75" subjects_at_risk="240"/>
                <counts group_id="E4" events="245" subjects_affected="68" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="148" subjects_affected="148" subjects_at_risk="505"/>
                <counts group_id="E2" events="65" subjects_affected="65" subjects_at_risk="249"/>
                <counts group_id="E3" events="72" subjects_affected="72" subjects_at_risk="240"/>
                <counts group_id="E4" events="73" subjects_affected="73" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="257" subjects_affected="257" subjects_at_risk="505"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="249"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="240"/>
                <counts group_id="E4" events="123" subjects_affected="123" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site ecchymosis</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="505"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="240"/>
                <counts group_id="E4" events="25" subjects_affected="25" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

